ProMIS Neurosciences presents educational webcast that will outline recent progress in understanding origins of Alzheimer's disease on Thursday, October 29, 2015 at 11:00 AM Eastern Time
TORONTO, Oct. 27, 2015 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN), announced today that it will be holding a live webcast entitled "Alzheimer's, Light at the End of the Tunnel" on Thursday, Oct. 29th, at 11:00 AM Eastern Time. The thirty minute webcast will include a 15 minute video/slide presentation followed by a 15 minute Question and Answer session with ProMIS Neurosciences senior management team.
This educational webcast will outline exciting recent progress in understanding the origins of Alzheimer's disease. In particular, the presentation will focus on the recent evidence and growing consensus in the scientific community highlighting the role played by toxic, propagating strains of misfolded proteins beta amyloid and tau in the development of Alzheimer's. Identification of these propagating, misfolded proteins (prions) opens the door to achieving early diagnosis and effective treatment via development of strain specific therapeutic antibodies and related companion diagnostics.
To access the live webcast on Thurs., Oct. 29th, participants should go to the following link and register as a guest: https://email@example.com/alzheimers. For those unable to join the live webcast, the recorded video/slide presentation can be accessed after the webcast via the following link: https://vimeo.com/user45047273.
About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision medicine solutions for the early detection and effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.
ProMIS uses its computational discovery platform— ProMIS™ --to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns the exclusive rights to the genus patent relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE ProMIS Neurosciences Inc.
For further information: please consult: The Company's website at: www.promisneurosciences.com, LinkedIn: https://www.linkedin.com/company/promis-neurosciences, Twitter: https://twitter.com/ProMISinc, or Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. 415 341-5783, Elliot.firstname.lastname@example.org